Baseball star Alex Rodriguez had an opportunity to be perhaps the greatest player of the past decade or even longer -- that was until he threw it all away by admitting to steroid use in 2009 and after being linked to the BioGenesis scandal that broke in January.
Being a Yankee and the man that signed the biggest contract in MLB history in 2007 -- a $275 million deal over 10 years -- Rodriguez was already a marked man that few MLB fans liked. Following his admission of using performance-enhancing substance beginning in 2001, and being linked to South Floridian anti-aging clinic BioGenesis along with more than a dozen other MLB and minor league players as user of human growth hormone and other illegal substances, disgust might be far too polite a word to describe the fans' current view of Rodriguez. To put this in a different perspective, in Rodriguez's first game back following hip surgery on Tuesday he was hit by a pitch in Chicago, and the crowd actually cheered!
Unfortunately, the fall of Alex Rodriguez isn't unique. The use of performance-enhancing drugs to get an edge has become all-too-common in sports like baseball and football, as well as global events like the Olympics. Let's not forget that Rodriguez shares a spot in infamy right alongside cyclist Lance Armstrong who admitted to steroid usage on Oprah! in January, while Olympic track star Marion Jones admitted to steroid usage all the way back in 2007.
Not only is PED usage a multi-sport problem, but the lengths at which players are going about securing these drugs, following their development by pharmaceutical companies that are oblivious to their misuse, and circumventing the current testing technology, is stunningly scary.
However, that may be about to change, as Alex Rodriguez's long-tenured link to doping could be the impetus that finally encourages dramatic change and pushes drugmakers and the World Anti-Doping Agency (WADA) together to combat PED abuse.
We've already seen examples in the past of drugmakers and WADA working hand-in-hand to clean up various sporting events. Two drugmakers that have led the charge are Roche (OTC:RHHBY) and GlaxoSmithKline (NYSE:GSK).
The move toward cooperation with WADA is pretty easy to understand for Roche, because it developed an anemia drug called Mircera, better known as CERA, which was primarily taken by cyclists to aid in the production of red blood cells, thus improving oxygen flow and stamina.
Glaxo, on the other hand, followed Roche's lead in testing for CERA by becoming the official anti-doping sponsor for the 2012 London Games, and has agreed to share proprietary information on all of its new drugs prone to abuse with WADA going forward.
You might think that it'd be easy to concoct a diagnostic test capable of detecting a synthetic drug from the body's own production of chemicals, but it's actually quite difficult depending on the chemical markers and the amount of the PED being used. In fact, many of these drugmakers, like Roche, needed years to develop diagnostic tests for their drugs. Ultimately, though, the Food and Drug Administration often requires drug developers to detail the pathway by which a new drug cycles through the body during the drug approval process which is the basics for developing an anti-doping test. Yet not all drugmakers were as accommodative as Roche or Glaxo with developing a PED test for their drug.
Take Amgen (NASDAQ:AMGN) for example. Amgen, maker of erythropoietin-stimulating drugs designed to treat anemia in kidney dialysis and cancer patients, did developed a diagnostic test for its anemia drug, Aranesp. That wasn't, however, until well after some coaxing from anti-doping agencies to do so and long after it actually sponsored a cycling event at a time when EPO (what Lance Armstrong used) was being abused within the cycling world.
This sector is welcoming tougher PED testing
While there could be some potential of lost sales for these drugmakers with regard to cheaters in these sports, the benefits of more stringent PED testing should more than outweigh these costs. For one, Glaxo and Roche's collaborative efforts could translate into increased sales if they develop the diagnostic kit used to test athletes. Major League Baseball, especially, needs to step in with considerably tougher PED-testing regimens to restore faith in the sport with its fans. As these sports look to clean up their act, companies like Glaxo and Roche could shine.
In addition, the positive public image of working side-by-side with anti-doping agencies to clean up sports can provide an intangible market value that can't be expressed in words. Just as consumers prefer to shop at stores they trust, or that are local, Roche and Glaxo's collaboration with WADA adds a level of transparency not often seen from a pharmaceutical company which could help enhance shareholder value.